Contact this trialFirst, we need to learn more about you.
Vitamin A Derivative
ALK-001 for Stargardt Disease
Recruiting0 awardsPhase 2
Los Angeles, California
This trial is exploring the long term safety and effectiveness of a treatment for Stargardt disease, a genetic disorder that causes vision loss. The treatment, ALK-001 (C20-D3-retinyl acetate), is being given to patients 8 to 70 years old to see if it slows the progression of the disease. The trial is funded by the FDA's Office of Orphan Products Development.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.